Trial · NCT02892149
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) | Vadadustat | 0.19 | Standard Error 0.032 | Grams per deciliter (g/dL) | |
| Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) | Darbepoetin Alfa | 0.36 | Standard Error 0.032 | Grams per deciliter (g/dL) | |
| Median Time to First Major Adverse Cardiovascular Event (MACE) | Vadadustat | 48.86 | Inter-Quartile Range 26.43 to 79.71 | Weeks | |
| Median Time to First Major Adverse Cardiovascular Event (MACE) | Darbepoetin Alfa | 48.00 | Inter-Quartile Range 22.43 to 75.57 | Weeks | |
| Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52) | Vadadustat | 0.23 | Standard Error 0.035 | g/dL | |
| Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52) | Darbepoetin Alfa | 0.41 | Standard Error 0.033 | g/dL | |
| Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis | Vadadustat | 43.29 | Inter-Quartile Range 21.86 to 73.14 | Weeks | |
| Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis | Darbepoetin Alfa | 45.21 | Inter-Quartile Range 22.29 to 73.86 | Weeks | |
| Median Time to First Cardiovascular MACE | Vadadustat | 44.57 | Inter-Quartile Range 23.29 to 81.86 | Weeks | |
| Median Time to First Cardiovascular MACE | Darbepoetin Alfa | 43.57 | Inter-Quartile Range 20.71 to 73.93 | Weeks | |
| Median Time to First Cardiovascular Death | Vadadustat | 46.14 | Inter-Quartile Range 29.43 to 79.00 | Weeks | |
| Median Time to First Cardiovascular Death | Darbepoetin Alfa | 47.64 | Inter-Quartile Range 24.57 to 74.14 | Weeks | |
| Median Time to First All-cause Mortality | Vadadustat | 50.79 | Inter-Quartile Range 30.29 to 80.50 | Weeks | |
| Median Time to First All-cause Mortality | Darbepoetin Alfa | 50.43 | Inter-Quartile Range 26.14 to 78.86 | Weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02892149/results